MAPT and Alzheimer disease: In AD patients at Braak stages V-VI, significant PTMs, such as phosphorylation at S262 and S263; acetylation at K311, K353, and K369; and ubiquitination at K259, K267, K311, and K317, are associated with increased tau and amyloid burdens (Wesseling et al., 2020).